Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2012; 18(36): 5058-5064
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5058
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5058
Table 3 5q31 and nucleotide-binding oligomerization domain 2/caspase activation recruitment domain 15 variants in crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab
| Variant | Remaining in remission following discontinuing infliximab (n = 6) | Lost remission following discontinuing infliximab (n = 8) | Odds ratio | P value |
| Arg702Trp | 1.50 | 1.00 | ||
| Homozygous wild type, CC (%) | 4 (67) | 6 (75) | ||
| Heterozygous, CT (%) | 2 (33) | 2 (25) | ||
| Homozygous mutant, TT (%) | 0 | 0 | ||
| Gly908Arg | - | - | ||
| Homozygous wild type, GG (%) | 6 (100) | 8 (100) | ||
| Leu1007fs insC | 2 (33) | 2 (25) | 1.50 | 1.00 |
| IGR2060a1 | 1.67 | 1.00 | ||
| Homozygous wild type, GG (%) | 1 (17) | 2 (25) | ||
| Heterozygous, GC (%) | 3 (50) | 2 (25) | ||
| Homozygous mutant, CC (%) | 2 (33) | 4 (50) | ||
| IGR3081a1 | - | 0.47 | ||
| Homozygous wild type, TT (%) | 0 | 2 (25) | ||
| Heterozygous, GT (%) | 4 (66) | 2 (25) | ||
| Homozygous mutant, GG (%) | 2 (33) | 4 (50) | ||
-
Citation: Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN. Crohn’s disease genotypes of patients in remission
vs relapses after infliximab discontinuation. World J Gastroenterol 2012; 18(36): 5058-5064 - URL: https://www.wjgnet.com/1007-9327/full/v18/i36/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i36.5058